Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Document Type
- Journal article (5)
Language
- English (5)
Keywords
- chemotherapy (2)
- children (2)
- Adolescents (1)
- Chemotherapy (1)
- Childhood medulloblastoma (1)
- Childrens-cancer (1)
- Clinical trial (1)
- EU-RHAB registry (1)
- High-dose chemotherapy (1)
- Medulloblastoma (1)
- Paediatric (1)
- Phase-II (1)
- Primitive neuroectodermal (1)
- RTPS1 (1)
- RTPS2 (1)
- Radiotherapy (1)
- Recurrent medulloblastoma (1)
- Reirradiation (1)
- Relapse (1)
- Secondary tumours (1)
- Survival (1)
- Therapy (1)
- Treatment (1)
- Trial (1)
- Tumors (1)
- adverse events (1)
- atypical teratoid rhabdoid tumors (1)
- brain cancer (1)
- childhood cancer (1)
- ependymoma (1)
- extracranial malignant rhabdoid tumor (1)
- germline mutation (1)
- imaging changes (1)
- intraventricular therapy (1)
- medulloblastoma (1)
- proton beam therapy (1)
- radiotherapy (1)
- re-irradiation (1)
- recurrence (1)
- recurrent (1)
- refractory (1)
- sirolimus (1)
- surgery (1)
Recurrent medulloblastomas are associated with survival rates <10%. Adequate multimodal therapy is being discussed as having a major impact on survival. In this study, 93 patients with recurrent medulloblastoma treated in the German P-HIT-REZ 2005 Study were analyzed for survival (PFS, OS) dependent on patient, disease, and treatment characteristics. The median age at the first recurrence was 10.1 years (IQR: 6.9–16.1). Median PFS and OS, at first recurrence, were 7.9 months (CI: 5.7–10.0) and 18.5 months (CI: 13.6–23.5), respectively. Early relapses/progressions (<18 months, n = 30/93) found mainly in molecular subgroup 3 were associated with markedly worse median PFS (HR: 2.34) and OS (HR: 3.26) in regression analyses. A significant survival advantage was found for the use of volume-reducing surgery as well as radiotherapy. Intravenous chemotherapy with carboplatin and etoposide (ivCHT, n = 28/93) showed improved PFS and OS data and the best objective response rate (ORR) was 66.7% compared to oral temozolomide (oCHT, n = 47/93) which was 34.8%. Intraventricular (n = 43) as well as high-dose chemotherapy (n = 17) at first relapse was not related to a significant survival benefit. Although the results are limited due to a non-randomized study design, they may serve as a basis for future treatment decisions in order to improve the patients' survival.